All In Biotech

Drug Trial Radar · NCT03097861

Evaluation of the Bioequivalence of Sprinkle and Capsule Formulations of Lubiprostone, as Compared to Placebo

A Randomized, Placebo-controlled, Double-blinded, Multicenter Study of the Bioequivalence of Sprinkle and Capsule Formulations of Lubiprostone, as Compared to Placebo, in Adult Subjects With Chronic Idiopathic Constipation

Last checked: Nov 19, 2026Latest source record: Jan 14, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 552 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

552

Actual

Start

Mar 13, 2017

Primary completion

Aug 17, 2017

Study completion Aug 17, 2017

Sponsor

Lead sponsor
Sucampo Pharma Americas, LLCIndustry
Sponsor type
Industry
Collaborators
Sucampo AG; Sucampo Pharmaceuticals, Inc.
First posted
Mar 31, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the bioequivalence of sprinkle and capsule formulations of lubiprostone, as compared to placebo, when administered orally in participants with Chronic Idiopathic Constipation (CIC).

Conditions

  • Chronic Idiopathic Constipation

Interventions

  • LubiprostoneDrug

    24 mcg administered orally BID

  • PlaceboDrug

    24 mcg administered orally BID

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Observed Spontaneous Bowel Movement (SBM) Count Within 1 WeekTime frame: during the 1-week treatment period

Locations

67 sites in 1 country. Site status is shown where the registry gives one.

  • Investigative Site

    Birmingham, Alabama

  • Investigative Site

    Foley, Alabama

  • Investigative Site

    Little Rock, Arkansas

  • Investigative Site

    Anaheim, California

  • Investigative Sitee

    Chula Vista, California

  • Investigative Site

    Garden Grove, California

  • Investigative Site

    Long Beach, California

  • Investigative Site

    Los Angeles, California

  • Investigative Site

    Panorama City, California

  • Investigative Site

    San Diego, California

  • Investigative Site

    San Marcos, California

  • Investigative Site

    Upland, California

  • Investigative Site

    Colorado Springs, Colorado

  • Investigative Site

    New London, Connecticut

  • Investigative Site

    Clearwater, Florida

  • Investigative Site

    Coral Springs, Florida

  • Investigative Site

    DeLand, Florida

  • Investigative Site

    Hialeah, Florida

  • Investigative Site

    Jupiter, Florida

  • Investigative Site

    Miami, Florida

  • Investigative Site 2

    Miami, Florida

  • Investigative Site

    Miami, Florida

  • Investigative Site

    Miami, Florida

  • Investigative Site

    Orlando, Florida

  • Investigative Site

    Plantation, Florida

  • Investigative Sitee

    Port Orange, Florida

  • Investigative Site

    Port Saint Lucie, Florida

  • Investigative Site

    Tampa, Florida

  • Investigative Site

    Tampa, Florida

  • Investigative Site

    West Palm Beach, Florida

  • Investigative Site

    Athens, Georgia

  • Investigative Site

    Snellville, Georgia

  • Investigative Site

    Stockbridge, Georgia

  • Investigative Site

    Blackfoot, Idaho

  • Investigative Site

    Boise, Idaho

  • Investigative Site

    Meridian, Idaho

  • Investigative Site

    Lake Charles, Louisiana

  • Investigative Site

    New Orleans, Louisiana

  • Investigative Site

    Shreveport, Louisiana

  • Investigative Site

    Chevy Chase, Maryland

Showing 40 of 67 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.